- Home
- NAGE vs FDMT Comparison
NAGE vs FDMT Comparison
Compare NAGE & FDMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NAGE | FDMT |
|---|---|---|
| Founded | 1999 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 507.6M | 513.6M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | NAGE | FDMT |
|---|---|---|
| Price | $5.08 | $8.50 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | $16.00 | ★ $34.13 |
| AVG Volume (30 Days) | ★ 992.1K | 753.7K |
| Earning Date | 01-01-0001 | 04-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $37,000.00 |
| Revenue This Year | $20.75 | $21,227.03 |
| Revenue Next Year | $19.96 | $161.87 |
| P/E Ratio | $21.29 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.73 | $2.24 |
| 52 Week High | $14.66 | $12.34 |
Technical Indicators
Market Signals| Indicator | NAGE | FDMT |
|---|---|---|
| Relative Strength Index (RSI) | 41.32 | 43.30 |
| Support Level | $4.74 | $8.11 |
| Resistance Level | $5.32 | $8.80 |
| Average True Range (ATR) | 0.29 | 0.57 |
| MACD | 0.04 | -0.14 |
| Stochastic Oscillator | 29.38 | 14.85 |
Price Performance
Historical ComparisonAbout NAGE Niagen Bioscience Inc.
Niagen Bioscience Inc is the leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. It is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. It is is clinically proven to increase NAD+ levels efficiently and effectively, and is the key ingredient powering our suite of Niagen brands.
About FDMT 4D Molecular Therapeutics Inc.
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.